1. Pink Sheet
  2. >>Product Reviews

Moment Of Truth For Belantamab Mafodotin, Trikafta And Turalio At EMA

 
• By Neena Brizmohun

A number of drug companies are set to learn the fate of their marketing authorization applications in the EU this week.

Wooden_Signpost
The EMA is deciding whether to recommend approval for a number of drugs • Source: Shutterstock

GlaxoSmithKline could find out this week whether the European Medicines Agency will recommend that its multiple myeloma drug belantamab mafodotin be approved in the EU, setting the company on course to becoming the first to market a BCMA-targeting therapy for the disease.

Belantamab mafodotin, which will also be considered for approval in the US next month, is among a number of products that are listed as being up for an opinion on...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Product Reviews

More from Pink Sheet

How Pharma Companies Can Mitigate The Impact Of US Tariffs On The Supply Chain

 
• By Ewan Townsend

If US tariffs on pharmaceutical supply chain products come into force they could be disruptive for companies. Ewan Townsend, of the international law firm Arnold & Porter, explains how companies can mitigate issues through negotiating with suppliers and reallocating tariff responsibilities.

‘The Question Is, What’s Going To Happen Next?’ – The Future For Biosimilars In Europe

 
• By Dave Wallace

With European biosimilars developers buoyed by recent regulatory moves, Medicines for Europe’s Isabell Remus and Julie Maréchal-Jamil discuss the next steps forward for the industry.